This activity has expired. Credit is no longer available.
This activity was supported by educational grants from Bristol-Myers Squibb Company and Merck Sharp & Dohme Corp.
Immune Checkpoint Inhibitor-Based Therapy as a Backbone in Cancer Treatment
Anthony J. Olszanski, MD, RPh
Fox Chase Cancer Center
Krista M. Rubin, MS, FNP-BC
Massachusetts General Hospital
Review the basic concepts of immunotherapy and the current treatment landscape; explore important aspects of IO care, including the microbiome, provider-patient communication, and survivorship; and evaluate emerging data for ICI-based combinations that are being explored in late-stage clinical trials.
|
|
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |
in collaboration with
  |